Literature DB >> 1592888

Inhibition of the morning cortisol peak abolishes the expected morning decrease in serum osteocalcin in normal males: evidence of a controlling effect of serum cortisol on the circadian rhythm in serum osteocalcin.

H K Nielsen1, K Brixen, M Kassem, P Charles, L Mosekilde.   

Abstract

Osteocalcin (OC) in serum varies in a remarkably constant circadian rhythm with zenith at night and nadir in the morning. The factors controlling this rhythm are unknown, but several studies indicate that serum cortisol could be of major importance. We tested this hypothesis in a double-blind, placebo-controlled, cross-over study comprising 10 normal male volunteers (aged 23-31 yr) by measuring the response in serum OC and cortisol rhythms to a single dose of metyrapone (30 mg/kg body weight) administered at midnight. During placebo, serum cortisol consistently peaked early in the morning before 0730 h. Ingestion of metyrapone at 2400 h significantly postponed and flattened this peak (P less than 0.01). On both occasions, serum OC increased towards peak levels around 0300 h (P less than 0.01) with no overall differences in the OC profiles. However, when the serum OC time series were synchronized according to the individual cortisol nadirs, we found a significant (P less than 0.01) decrease in serum OC on the placebo day approximately 4 h after the cortisol nadir, whereas no significant changes (P greater than 0.50) were seen on the metyrapone day. Moreover, the mean serum OC level tended to be higher (P less than 0.10 in the interval 0-12 h, and P = 0.06 in the interval 4-8 h) on the metyrapone day compared with the placebo day. On the placebo day, the mean level of serum cortisol during the interval 0-4 h correlated inversely with the mean level of serum OC in the interval 4-8 h (r = 0.77, P less than 0.05). This relation was not found on the metyrapone day. In conclusion, administration of metyrapone, which reduced and postponed the early morning cortisol peak, abolished the normal morning decrease in serum OC. This strongly supports that changes in endogenous serum cortisol are of major importance for the circadian rhythm in serum OC.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1592888     DOI: 10.1210/jcem.74.6.1592888

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Metabolic effects of the nocturnal rise in cortisol on carbohydrate metabolism in normal humans.

Authors:  S Dinneen; A Alzaid; J Miles; R Rizza
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

2.  Pharmacokinetic/pharmacodynamic modelling of effects of dexamethasone and prednisolone in combination with endogenous cortisol on lymphocyte counts and systemic markers of bone turn over and inflammation in healthy and asthmatic men.

Authors:  E F L Dubois; M G M Derks; D H Schweitzer; A H Zwinderman; P N R Dekhuijzen; C J van Boxtel
Journal:  Eur J Clin Pharmacol       Date:  2004-05-19       Impact factor: 2.953

3.  Distinct actions of prednisolone and dexamethasone towards osteocalcin and eosinophilic cationic protein in assumed clinically equivalent doses: a study in healthy men.

Authors:  E F L Dubois; M G M Derks; A H Zwinderman; P N R Dekhuijzen; C J Van Boxtel; D H Schweitzer
Journal:  Eur J Clin Pharmacol       Date:  2003-02-15       Impact factor: 2.953

4.  Effect of Ramadan fasting in Saudi Arabia on serum bone profile and immunoglobulins.

Authors:  Suhard M Bahijri; Ghada M Ajabnoor; Anwar Borai; Jumana Y Al-Aama; George P Chrousos
Journal:  Ther Adv Endocrinol Metab       Date:  2015-10       Impact factor: 3.565

5.  Effects of salmon calcitonin suppositories on bone mass and turnover in established osteoporosis.

Authors:  G Kollerup; A P Hermann; K Brixen; B E Lindblad; L Mosekilde; O H Sørensen
Journal:  Calcif Tissue Int       Date:  1994-01       Impact factor: 4.333

6.  The contribution of serum cortisone and glucocorticoid metabolites to detrimental bone health in patients receiving hydrocortisone therapy.

Authors:  Rosemary Dineen; Lucy-Ann Behan; Grainne Kelleher; Mark J Hannon; Jennifer J Brady; Bairbre Rogers; Brian G Keevil; William Tormey; Diarmuid Smith; Christopher J Thompson; Malachi J McKenna; Wiebke Arlt; Paul M Stewart; Amar Agha; Mark Sherlock
Journal:  BMC Endocr Disord       Date:  2020-10-10       Impact factor: 2.763

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.